Adding Immunomodulating Agents and Corticosteroids to Adalimumab Increases Risks of Infection for Patients With Crohn's Disease, Mayo Clinic Study Presented at American College of Gastroenterology
Doctor's Guide -- SAN ANTONIO, Tex -- October 21, 2010 -- The more classes of medication required to control Crohn's disease on top of treatment with the anti-tumour necrosis factor adalimumab the greater the risk of patients experiencing serious infections, researchers stated here at the 75th Annual Meeting of the American College of Gastroenterology (ACG).